The FDA and Drug Enforcement Administration are calling on stakeholders throughout the pharmaceutical supply chain to do all they can to boost available quantities of stimulant medications for the treatment of ADHD, binge-eating and narcolepsy, according to an Aug. 1 joint statement.
